Friday , January 19 2018
Home / David L. Joffe, BSPharm, CDE, FACA (page 27)

David L. Joffe, BSPharm, CDE, FACA

David L. Joffe, BSPharm, CDE, FACA

(Editor-in-Chief Diabetes In Control) A graduate of University of Kentucky College of Pharmacy, he has practiced in the Tampa Bay area since 1986, has been providing diabetes and cardiovascular care in Tampa Bay since 1995, and spent 2 years as an Eckerd Patient Care Pharmacist managing over 100 diabetes patients. Dave currently sees patients in over 30 primary care and endocrinologists offices.

Diabetes Education, Part 1

In this week’s Homerun Slides series, we have a special set of slides from our editor-in-chief, Dave Joffe, who has put together a brief series on education. In this first set of slides, which are designed for educators to help younger patients with type 1 better understand their diabetes, how …

Read More »

Mechanisms and Receptors Controlling Intestinal GLP-1 Secretion, Part 2

David Joffe, BSPharm, CDE  Brittany Davis, Pharm D Candidate, Presbyterian College School of Pharmacy The molecular mechanisms linking fatty acids to GLP-1 secretion from gut endocrine cells remain incompletely understood. Hirasawa and colleagues have identified a GPCR, designated GPR120 that serves as a receptor for fatty acids on gut endocrine cells. …

Read More »

Medical ID Bracelet

Report_Now

A new patient, a young man recently diagnosed with diabetes, was aware of the problems associated with alcohol and hypoglycemia but liked to go out with friends on the weekend.  I stressed the need for a medical ID bracelet and after a couple of visits he did purchase one. It …

Read More »

ADA 2013: Dapagliflozin Update

Durability of Dapagliflozin vs. Glipizide as Add-On Therapies in T2DM Inadequately Controlled on Metformin: 4-Year Data   The efficacy, tolerability and safety of dapagliflozin was studied compared to glipizide over a period of 4 years. Dapagliflozin is a novel medication that is a highly selective inhibitor of SLGLT2 and reduces …

Read More »

ADA 2013: Empagliflozin Update

Boehringer Ingelheim Pharmaceuticals, Inc., and Eli Lilly and Company are working together to pave a new pathway for type 2 diabetes patients with the sodium glucose co-transporter 2 (SGLT2) inhibitor, empagliflozin. The investigational agent is currently in Phase III clinical trials focusing on four pivotal trials that have concluded with …

Read More »